High Tech Pharm Co., Ltd. (KOSDAQ:106190)
South Korea · Delayed Price · Currency is KRW 14,400
+100 (0.70%)
At close: Jun 11, 2026
High Tech Pharm Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 69,050 | 70,183 | 77,513 | 76,772 | 102,947 | 73,287 |
Other Revenue | - | - | - | -0 | - | - |
| 69,050 | 70,183 | 77,513 | 76,772 | 102,947 | 73,287 | |
Revenue Growth (YoY) | -6.15% | -9.46% | 0.97% | -25.43% | 40.47% | -1.58% |
Cost of Revenue | 53,140 | 53,246 | 58,032 | 63,938 | 95,177 | 70,216 |
Gross Profit | 15,911 | 16,937 | 19,481 | 12,834 | 7,770 | 3,071 |
Selling, General & Admin | 5,601 | 3,122 | 3,790 | 2,601 | 2,705 | 3,310 |
Research & Development | 966.49 | 816.56 | - | - | - | - |
Other Operating Expenses | 61.58 | 62.15 | 59.44 | 61.83 | 47.33 | 115.54 |
Operating Expenses | 6,712 | 4,081 | 3,923 | 2,745 | 2,843 | 3,483 |
Operating Income | 9,198 | 12,856 | 15,558 | 10,089 | 4,927 | -412.02 |
Interest Expense | -90.11 | -180.16 | -787.27 | -896.47 | -463.69 | -252.07 |
Interest & Investment Income | 15.59 | 12.63 | 8 | 4.69 | 4.31 | 84.73 |
Currency Exchange Gain (Loss) | 578.71 | 5.76 | 1,871 | 278.34 | -829.89 | -290.52 |
Other Non Operating Income (Expenses) | 1,035 | 1,003 | 307.37 | 282.41 | 267.28 | 1.82 |
EBT Excluding Unusual Items | 10,738 | 13,697 | 16,957 | 9,758 | 3,905 | -868.07 |
Gain (Loss) on Sale of Investments | 132.65 | 127.32 | 129.57 | 115.56 | 54.65 | - |
Gain (Loss) on Sale of Assets | 3 | 3 | - | -9.51 | 68.11 | 0.14 |
Pretax Income | 10,874 | 13,828 | 17,087 | 9,864 | 4,028 | -867.94 |
Income Tax Expense | 1,850 | 2,353 | 3,377 | 1,787 | -1,845 | 357.46 |
Net Income | 9,024 | 11,475 | 13,710 | 8,076 | 5,873 | -1,225 |
Net Income to Common | 9,024 | 11,475 | 13,710 | 8,076 | 5,873 | -1,225 |
Net Income Growth | -28.53% | -16.30% | 69.75% | 37.52% | - | - |
Shares Outstanding (Basic) | - | 11 | 11 | 7 | 11 | 11 |
Shares Outstanding (Diluted) | - | 11 | 11 | 7 | 11 | 11 |
Shares Change (YoY) | - | 0.64% | 49.99% | -33.33% | - | - |
EPS (Basic) | - | 1079.24 | 1289.43 | 1139.33 | 552.32 | -115.24 |
EPS (Diluted) | - | 1072.37 | 1289.43 | 1139.33 | 552.32 | -115.24 |
EPS Growth | - | -16.83% | 13.17% | 106.28% | - | - |
Free Cash Flow | 2,030 | 15,102 | 12,558 | -2,183 | -4,359 | 6,068 |
Free Cash Flow Per Share | - | 1411.28 | 1181.10 | -307.89 | -409.94 | 570.68 |
Gross Margin | 23.04% | 24.13% | 25.13% | 16.72% | 7.55% | 4.19% |
Operating Margin | 13.32% | 18.32% | 20.07% | 13.14% | 4.79% | -0.56% |
Profit Margin | 13.07% | 16.35% | 17.69% | 10.52% | 5.71% | -1.67% |
Free Cash Flow Margin | 2.94% | 21.52% | 16.20% | -2.84% | -4.23% | 8.28% |
EBITDA | 14,679 | 18,273 | 20,727 | 15,075 | 10,472 | 5,139 |
EBITDA Margin | 21.26% | 26.04% | 26.74% | 19.64% | 10.17% | 7.01% |
D&A For EBITDA | 5,481 | 5,417 | 5,169 | 4,986 | 5,545 | 5,551 |
EBIT | 9,198 | 12,856 | 15,558 | 10,089 | 4,927 | -412.02 |
EBIT Margin | 13.32% | 18.32% | 20.07% | 13.14% | 4.79% | -0.56% |
Effective Tax Rate | 17.01% | 17.01% | 19.76% | 18.12% | - | - |
Advertising Expenses | - | 70.81 | 192.85 | 97.61 | 84.51 | 13.86 |